The use of hydroxyurea in the real life of MIOT network: an observational study

References

• Mabaera R, West RJ, Conine SJ, et al. A cell stress signaling model of fetal hemoglobin induction: what doesn’t kill red blood cells may make them stronger. Exp Hematol. 2008;36(9):1057–1072.
   PubMed Web of Science ®Google Scholar
• Algiraigri AH, Wright NAM, Paolucci EO, et al. Hydroxyurea for nontransfusion-dependent beta-thalassemia: a systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2017;10(3):116–125.
   PubMedGoogle Scholar
• Musallam KM, Taher AT, Cappellini MD, et al. Clinical experience with fetal hemoglobin induction therapy in patients with beta-thalassemia. Blood. 2013;121(12):2199–2212. quiz 2372.
   PubMed Web of Science ®Google Scholar
• Mancuso A, Maggio A, Renda D, et al. Treatment with hydroxycarbamide for intermedia thalassaemia: decrease of efficacy in some patients during long-term follow up. Br J Haematol. 2006;133(1):105–106.
   PubMed Web of Science ®Google Scholar
• Rigano P, Pecoraro A, Calzolari R, et al. Desensitization to hydroxycarbamide following long-term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients. Br J Haematol. 2010;151(5):509–515.
   PubMed Web of Science ®Google Scholar
• Taher A, Vichinsky E, Musallam K, et al. Guidelines for the management of non transfusion dependent Thalassaemia (NTDT). [Internet]. Nicosia Cyprus: Thalassaemia International Federation; 2013.
   Google Scholar
• Karimi M, Borzouee M, Mehrabani A, et al. Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia. Eur J Haematol. 2009;82(3):213–218.
   PubMed Web of Science ®Google Scholar
• Meo A, Cassinerio E, Castelli R, et al. Effect of hydroxyurea on extramedullary haematopoiesis in thalassaemia intermedia: case reports and literature review. Int J Lab Hematol. 2008;30(5):425–431.
   PubMed Web of Science ®Google Scholar
• Ricchi P, Costantini S, Spasiano A, et al. The long-term and extensive efficacy of low dose thalidomide in a case of an untransfusable patient with non-transfusion-dependent Thalassemia. Blood Cells Mol Dis. 2016;57:97–99.
   PubMed Web of Science ®Google Scholar
• Meloni A, Ramazzotti A, Positano V, et al. Evaluation of a web-based network for reproducible T2* MRI assessment of iron overload in thalassemia. Int J Med Inform. 2009;78(8):503–512.
   PubMed Web of Science ®Google Scholar
• Ramazzotti A, Pepe A, Positano V, et al. Multicenter validation of the magnetic resonance t2* technique for segmental and global quantification of myocardial iron. J Magn Reson Imaging. 2009;30(1):62–68.
   PubMed Web of Science ®Google Scholar
• Cogliandro T, Derchi G, Mancuso L, et al. Guideline recommendations for heart complications in thalassemia major. J Cardiovasc Med (Hagerstown). 2008;9(5):515–525.
   PubMed Web of Science ®Google Scholar
• Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440–1463.
   PubMed Web of Science ®Google Scholar
• Buxton AE, Calkins H, Callans DJ, et al. ACC/AHA/HRS 2006 key data elements and definitions for electrophysiological studies and procedures: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (ACC/AHA/HRS Writing Committee to Develop Data Standards on Electrophysiology). Circulation. 2006;114(23):2534–2570.
   PubMed Web of Science ®Google Scholar
• Taher AT, Musallam KM, El-Beshlawy A, et al. Age-related complications in treatment-naive patients with thalassaemia intermedia. Br J Haematol. 2010;150(4):486–489.
   PubMed Web of Science ®Google Scholar
• Ricchi P, Ammirabile M, Costantini S, et al. A useful relationship between the presence of extramedullary erythropoeisis and the level of the soluble form of the transferrin receptor in a large cohort of adult patients with thalassemia intermedia: a prospective study. Ann Hematol. 2012;91(6):905–909.
   PubMed Web of Science ®Google Scholar
• El-Beshlawy A, El-Ghamrawy M, El-e MA, et al. Response to hydroxycarbamide in pediatric beta-thalassemia intermedia: 8 years’ follow-up in Egypt. Ann Hematol. 2014;93(12):2045–2050.
   PubMed Web of Science ®Google Scholar
• Vitrano A, Calvaruso G, Lai E, et al. The era of comparable life expectancy between thalassaemia major and intermedia: is it time to revisit the major-intermedia dichotomy? Br J Haematol. 2017;176(1):124–130.
   PubMed Web of Science ®Google Scholar
• Spivak JL, Hasselbalch H. Hydroxycarbamide: a user’s guide for chronic myeloproliferative disorders. Expert Rev Anticancer Ther. 2011;11(3):403–414.
   PubMed Web of Science ®Google Scholar
• Chung WS, Lin CL, Lin CL, et al. Thalassaemia and risk of cancer: a population-based cohort study. J Epidemiol Community Health. 2015;69(11):1066–1070.
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Garani MC, Forni GL, et al. Hepatocellular carcinoma in thalassaemia: an update of the Italian registry. Br J Haematol. 2014;167(1):121–126.
   PubMed Web of Science ®Google Scholar
• Marsella M, Ricchi P. Thalassemia and hepatocellular carcinoma: links and risks. J Blood Med. 2019;10:323–334.
   PubMed Web of Science ®Google Scholar
• Halawi R, Beydoun H, Cappellini MD, et al. Hematologic malignancies in thalassemia: adding new cases to the repertoire. Am J Hematol. 2017;92(5):E68–70.
   PubMed Web of Science ®Google Scholar
• Ricchi P, Ammirabile M, Costantini S, et al. Longitudinal trend analysis of serum transferrin receptor-1 level in a cohort of patients affected by non-transfusion dependent thalassaemia. Br J Haematol. 2019;186(5):e121–e123.
   PubMed Web of Science ®Google Scholar
• Ricchi P, Ammirabile M, Costantini S, et al. Soluble form of transferrin receptor as a biomarker of overall morbidity in patients with non-transfusion-dependent thalassaemia: a cross-sectional study. Blood Transfus. 2016;14(6):538–540.
   PubMed Web of Science ®Google Scholar
• Ricchi P, Meloni A, Costantini S, et al. Soluble form of transferrin receptor-1 level is associated with the age at first diagnosis and the risk of therapeutic intervention and iron overloading in patients with non-transfusion-dependent thalassemia. Ann Hematol. 2017;96:1541–1546.
   PubMed Web of Science ®Google Scholar
• Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood. 2010;115(26):5300–5311.
   PubMed Web of Science ®Google Scholar
• Taher A, Isma’eel H, Cappellini MD. Thalassemia intermedia: revisited. Blood Cells Mol Dis. 2006;37(1):12–20.
   PubMed Web of Science ®Google Scholar
• Baldini M, Marcon A, Cassin R, et al. Beta-thalassaemia intermedia: evaluation of endocrine and bone complications. Biomed Res Int. 2014;2014:174581.
   PubMed Web of Science ®Google Scholar
• Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood. 2010;115(10):1886–1892.
   PubMed Web of Science ®Google Scholar
• Panigrahi I, Marwaha RK, Kulkarni K. The expanding spectrum of thalassemia intermedia. Hematology. 2009;14(6):311–314.
   PubMed Web of Science ®Google Scholar
• Pourfarzad F, von Lindern M, Azarkeivan A, et al. Hydroxyurea responsiveness in beta-thalassemic patients is determined by the stress response adaptation of erythroid progenitors and their differentiation propensity. Haematologica. 2013;98(5):696–704.
   PubMed Web of Science ®Google Scholar
• Musallam KM, Cappellini MD, Daar S, et al. Morbidity-free survival and hemoglobin level in non-transfusion-dependent β-thalassemia: a 10-year cohort study. Ann Hematol. 2022 Jan;101(1):203–204.
   PubMed Web of Science ®Google Scholar
• Taher AT, Musallam KM, Cappellini MD, et al. Optimal management of beta thalassaemia intermedia. Br J Haematol. 2011 Mar;152(5):512–523.
   PubMed Web of Science ®Google Scholar
• Ricchi P, Meloni A, Pistoia L, et al. Longitudinal follow-up of patients with thalassaemia intermedia who started transfusion therapy in adulthood: a cohort study. Br J Haematol. 2020;191(1):107–114.
   PubMed Web of Science ®Google Scholar
• Piga A, Perrotta S, Gamberini MR, et al. Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with beta-thalassemia. Blood. 2019;133(12):1279–1289.
   PubMed Web of Science ®Google Scholar
• Taher AT, Cappellini MD, Kattamis A, et al. The beyond study: results of a Phase 2, double-blind, randomized, placebo-controlled multicenter study of luspatercept in adult patients with non-transfusion dependent beta-thalassemia. EHA Library. 2021. https://library.ehaweb.org/eha/2021/eha2021-virtual-congress/324509.
   Google Scholar